Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

ospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA or foreign authority regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of the initiation
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis , ... laser tattoo removal experience with the advanced Astanza Duality laser and ... quality cosmetic services with cutting edge medical technology and offering expert ... has seen a dramatic increase in the presence of ...
(Date:1/14/2014)... -- Acumed,s new SLIC Screw System - a jointed ... place and insert the screw accurately - offers surgeons ... repair or reconstruction as it holds the bones reduced ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw is ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: ... congratulations to the four winners of the International BioGENEius ... an exemplary understanding of biotechnology through science research projects. ... Challenge since its inception in the early 1990s. Sanofi ...
... Shield LLC today announced the new SILVER STORM™ waterproof, ... with other infection prevention products, at the APIC infection ... been designed to help prevent cross contamination infections which ... According to a bacteria study of common touch ...
Cached Medicine Technology:Sanofi Pasteur Commends Winners of International BioGENEius Challenge 2Sanofi Pasteur Commends Winners of International BioGENEius Challenge 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... undergo abdominal/pelvic computed tomography (CT) receive unindicated and unnecessary ... according to a study presented today at the annual ... "It is the responsibility of all physicians who ... is as low as reasonably achievable without compromising the ...
... ATLANTA, Nov. 29 The following is an investment ... Intellivest Securities Research, Inc., ("ISR") a Georgia registered investment ... BIOC) which serves companies in the pharmaceutical, biotechnology and ... their clients manage, process and submit medical imaging portions ...
... blamed for something leads to more self-defensive finger pointing, study ... game is a contagious one, a new study reports, even ... people see someone blame someone else for a problem, even ... engage in blaming others, too. , "When we see ...
... , , CHICAGO, Nov. 28 Welcome ... PACS solution for the clinical routine from Siemens Healthcare. ... from Siemens where 2D, 3D, and 4D reading come together in one place, ... multimodality images are read today. Siemens is unveiling this innovation at ...
... Mass., Nov. 27 GSI Group Inc. (Pink Sheets: GSIGQ)(the ... today announced that an annual meeting of the Company,s shareholders ... time and location of the meeting will be announced in ... requisition notice from Stephen Bershad, a holder of greater than ...
... , , ROCHESTER, N.Y., Nov. 27 ... and fortunately every year, new vaccines are being added to ... for the same period of time? And, if not, when ... , In this month,s issue of Pediatrics, the Journal ...
Cached Medicine News:Health News:Unindicated CT series result in unnecessary radiation exposure for patients 2Health News:Unindicated CT series result in unnecessary radiation exposure for patients 3Health News:Research Report on BioClinica, Inc. as Speculative Buy 2Health News:When Accusations Start to Fly, They Multiply 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3
With this more compact transducer face, this is the transducer of choice for obstetric imaging in areas with a small acoustic window....
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
... The OPTI LION is a compact ... single-use cassettes instead of reagents or ... patient sample is analyzed., ,In addition ... the OPTI LION measures ionized calcium ...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
Medicine Products: